Overview of Dual Targeting Nanostructured Lipid Carriers for the Treatment of Ovarian Cancer (Record no. 15549)

MARC details
000 -LEADER
fixed length control field a
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20211123093528.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 211123b xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency AIKTC-KRRC
Transcribing agency AIKTC-KRRC
100 ## - MAIN ENTRY--PERSONAL NAME
9 (RLIN) 14741
Author Mandadhi, Praharsh Kumar Rajendra
245 ## - TITLE STATEMENT
Title Overview of Dual Targeting Nanostructured Lipid Carriers for the Treatment of Ovarian Cancer
250 ## - EDITION STATEMENT
Volume, Issue number Vol.55(2), Apr-Jun
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Banaglore
Name of publisher, distributor, etc. Association of Pharmaceutical Teachers of India (APTI)
Year 2021
300 ## - PHYSICAL DESCRIPTION
Pagination 330-335p.
520 ## - SUMMARY, ETC.
Summary, etc. Purpose: To summarize main findings from research on oral delivery of Nanostructured lipid carriers targeting ovarian cancer. Methods: A narrative review of all the relevant papers known to author was conducted. Results: Ovarian cancer is one of the most common gynaecologic cancer, the frontline treatments for which are surgical approach followed by radiotherapy or chemotherapy. Chemotherapy has its own limitations; consequently, there is a need to develop a targeted drug delivery system with high efficacy. Preclinical evidence suggests that combination therapies are likely to be effective in ovarian cancer. However, from clinical reports, it is evident that chemotherapeutic drugs have lower therapeutic value for the treatment of ovarian cancer. We propose that these limitations can be overcome by a novel formulation consisting of nanostructured lipid carriers. Recent pharmacological research has successfully potentiated the effects of combination therapy in acute animal preparations by inhibiting proteins that are involved in different physiological pathways of cancer cells. Conclusion: We have reviewed the scope of nanostructured lipid carriers concerning chemotherapy of ovarian cancer. The advantages of oral administration of these lipid carriers are discussed. Also, the various nano-lipid formulations and combination therapies reported along with their therapeutic outcomes have been reviewed. In light of this, nanostructured lipid carriers containing two different active ingredients for oral administration could be a potential approach for the effective treatment of ovarian cancer.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 4639
Topical term or geographic name entry element PHARMACEUTICS
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 14742
Co-Author Natarajan, Jawahar
773 0# - HOST ITEM ENTRY
International Standard Serial Number 0019-5464
Title Indian journal of pharmaceutical education and research
Place, publisher, and date of publication Bengluru Association of Pharmaceutical Teachers of India (APTI)
856 ## - ELECTRONIC LOCATION AND ACCESS
URL https://www.ijper.org/sites/default/files/IndJPhaEdRes-55-2-330.pdf
Link text Click here
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Articles Abstract Database
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Barcode Date last seen Price effective from Koha item type
    Dewey Decimal Classification     School of Pharmacy School of Pharmacy Archieval Section 23/11/2021   2021-2022354 23/11/2021 23/11/2021 Articles Abstract Database
Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.